State of the Art
New therapies for asthma: Where next?
Douglas S. Robinson MA, MD, FRCP,
Corresponding Author
Douglas S. Robinson MA, MD, FRCP
Departments of Allergy and Clinical Immunology and Leukocyte Biology, National Heart and Lung Institute and Basic Medical Sciences Division, Faculty of Medicine, Imperial College London, and Royal Brompton and St. Mary's NHS Trusts, London, UK
Basic Medical Sciences Division, Faculty of Medicine, Imperial College London, Dovehouse St., London SW3 6LY, UK.Search for more papers by this authorDouglas S. Robinson MA, MD, FRCP,
Corresponding Author
Douglas S. Robinson MA, MD, FRCP
Departments of Allergy and Clinical Immunology and Leukocyte Biology, National Heart and Lung Institute and Basic Medical Sciences Division, Faculty of Medicine, Imperial College London, and Royal Brompton and St. Mary's NHS Trusts, London, UK
Basic Medical Sciences Division, Faculty of Medicine, Imperial College London, Dovehouse St., London SW3 6LY, UK.Search for more papers by this author
REFERENCES
- 1 British guideline on the management of asthma. Thorax [Suppl] 2003; 58: 1–83.
- 2 Kay AB. Allergy and allergic diseases. N Engl J Med 2001; 344: 30–37, 109–113.
- 3 Busse WW, Lemanske RF. Asthma. N Engl J Med 2001; 344: 350–362.
- 4 Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348–2357.
- 5 Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, Kay AB. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20: 528–533.
- 6 Krawiec ME, Westcott JY, Chu HW, Balzar S, Trudeau JB, Schwartz LB, Wenzel SE. Persistent wheezing in very young infants is associated with lower respiratory inflammation. Am.J Respir Crit Care Med 2001; 163: 1338–1343.
- 7 Stevenson EC, Turner G, Heaney LG, Schock BD, Taylor R, Gallagher T, Ennis M, Shields MD. Bronchoalveolar lavage findings suggest two different forms of childhood asthma. Clin Exp Allergy 1997; 27: 1027–1035.
- 8 Gemou-Engesaeth V, Kay AB, Bush A, Corrigan CJ. Activated peripheral blood CD4 and CD8 T-lymphocytes in child asthma: correlation with eosinophilia and disease severity. Pediatr Allergy Immunol 1994; 5: 170–177.
- 9 Gemou-Engesaeth V, Bush A, Kay AB, Hamid Q, Corrigan CJ. Inhaled glucocorticoid therapy of childhood asthma is associated with peripheral blood T cell activation and Th2-type cytokine mRNA expression. Pediatrics 1997; 99: 695–703.
- 10 Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164: 12–17.
- 11 Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828–1834.
- 12 Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Fowler-Taylor A, Rohane P. Treatment of childhood asthma with anti-immunogolbulin E antibody (omalizumab). Pediatrics 2001; 108: E36.
- 13 Lemanske RF, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002; 110: E55.
- 14 Busse WW, Corren J, Lanier Q, McAlary M, Fowler-Taylor A, Della Chioppa G, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanised monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–190.
- 15 Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirwell J, Gupta N, Della Chioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirements in allergic asthmatics. Eur Respir J 2001; 18: 254–261.
- 16 Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirwell J, Della Chioppa G. Omalizumab provides long-term control in patients with moderate to severe allergic asthma. Eur Respir J 2002; 20: 73–78.
- 17 Walker S, Monteil M, Lasserson T, Phelan K, Walters H. Anti-IgE for chronic asthma. The Cochrane Library; Issue 3, 2003. Oxford: Update Software.
- 18 Leung DYM, Sampson HA, Yuninger JW, Burks AW, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348: 986–993.
- 19 Lloyd CM, Gonzalo JA, Coyle AJ, Gutierrez-Ramos JC. Mouse models of allergic airway disease. Adv Immunol 2001; 77: 263–295.
- 20 Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160: 1816–1823.
- 21 Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM, IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963–970.
- 22 Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM. Preclinical efficacy and safety of paascolizumab (SB 240683): a humanised anti-interleukin 4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130: 93–100.
- 23 Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258–2261.
- 24 Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261–2263.
- 25 Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144–2148.
- 26 Kips JC, Brian OJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA. The effect of SCH55700, a humanized anti-hIL-5 antibody in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; e-publication ahead of print.
- 27 Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199–204.
- 28 Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111: 714–719.
- 29 Gregory B, Kirchem A, Phipps S, Gevaert P, Pridgeon C, Rankin SM, Robinson DS. Differential regulation of human eosinophil IL-3, IL-5 and GM-CSF receptor alpha chain expression by cytokines: IL-3, IL-5 or GM-CSF down regulate IL-5Rα expression with loss of IL-5 responsiveness, but up-regulate IL-3Rα expression. J Immunol 2003; 170: 5359–5366.
- 30 Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, Jarjour NN, Busse WW, Kelly EA. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002; 169: 6452–6458.
- 31 Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001–1008.
- 32 Payne DNR, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult to treat asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001; 164: 1376–1381.
- 33 Ying S, Robinson DS, Varney V, Meng Q, Tsicopoulos A, Moqbel R, Durham SR, Kay AB, Hamid Q. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 21: 745–750.
- 34
Babu K,
Arshad SH,
Howarth PH,
Chauhan AJ,
Bell EJ,
Puddicombe S,
Davies DE,
Holgate ST.
Soluble tumor necrosis factor alpha (TNF-alpha) receptor (Enbrel) as effective therapeutic strategy in chronic severe asthma.
J Allergy Clin Immunol
2003;
111:
838.
10.1016/S0091-6749(03)80997-1 Google Scholar
- 35 Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J, Warrington SJ, Renzetti L, Rames A, Bock JA, Boyce MJ, Hansel TT, Holgate ST, Barnes PJ. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2149–2153.
- 36 Menzies-Gow A, Robinson DS. Eosinophil chemokines and their receptors: an attractive target in asthma? Lancet 2000; 355: 1741–1743.
- 37 Frankland AW, Augustin R. Prophylaxis of summer hayfever and asthma. A controlled trial comparing crude grass pollen extracts with the isolated main protein component. Lancet 1954; i: 1055–1057.
- 38 Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term efficacy of grass pollen immunotherapy. N Engl J Med 1999; 341: 468–475.
- 39 Walker SM, Pajno GB, Torres Lima M, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomised, controlled trial. J Allergy Clin Immunol 2001; 107: 87–93.
- 40 Creticos PS, Reed CE. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334: 501–506.
- 41 Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54: 1022–1041.
- 42 Committee on Safety of Medicines/Medicines Control Agency. Desensitising vaccines. Br Med J [Clin Res] 1986; 293: 948.
- 43 Reid MJ, et al. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993; 92: 6–15.
- 44 Tari MG, Mancino M, Ghezzi E, Frank E, Cromwell O. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study. Allergy 1997; 52: 65–74.
- 45 Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2: 446–453.
- 46 Larché M. Inhibition of human T-cell responses by allergen peptides. Immunology 2001; 104: 377–382.
- 47 Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154: 1623–1628.
- 48 Oldfield WLG, Larche M, Kay AB. Effect of T cell peptides derived from Fel d1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360: 47–53.
- 49 Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189: 1885–1894.
- 50 Horner AA, Raz E. Immunostimulatory sequence oligonucleotide-based vaccination and immunomodulation: two unique but complimentary strategies for the treatment of allergic diseases. J Allergy Clin Immunol 2002; 110: 706–712.
- 51
Creticos PS,
Lighvani SS,
Bieneman AP,
Balcer-Whaley SL,
Norman PS,
Lichtenstein LM,
Schroeder JT.
Enhanced IL-10 secretion by PBMC during the ragweed season: effect of AIC immunotherapy vs placebo.
J Allergy Clin Immunol
2003;
111:
530.
10.1016/S0091-6749(03)80689-9 Google Scholar
- 52 Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, Bowen G, Rook G, Walker C. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002; 8: 625–629.
- 53 Camporota L, Corkhill A, Long H, Lordan J, Stanciu L, Tuckwell N, Cross A, Stanford JL, Rook GAW, Holgate ST, Djukanovic R. The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 2003; 21: 287–293.
- 54 Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a staandradised Dematophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitisations in children. J Allergy Clin Immunol 1997; 99: 450–453.
- 55 Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jaconsen L, Koivikko A, Koller DY, Niggeman B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002; 109: 251–256.
Citing Literature
